Lorenz Waldmeier

1.2k total citations · 1 hit paper
17 papers, 910 citations indexed

About

Lorenz Waldmeier is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Lorenz Waldmeier has authored 17 papers receiving a total of 910 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Oncology and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Lorenz Waldmeier's work include Monoclonal and Polyclonal Antibodies Research (8 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Cancer Cells and Metastasis (4 papers). Lorenz Waldmeier is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (8 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Cancer Cells and Metastasis (4 papers). Lorenz Waldmeier collaborates with scholars based in Switzerland, United States and Germany. Lorenz Waldmeier's co-authors include Gerhard Christofori, Phil Arnold, Erik van Nimwegen, Nathalie Meyer‐Schaller, Neha Tiwari, Vijay Tiwari, Dirk Schübeler, Mikhail Pachkov, Piotr J. Balwierz and Maren Diepenbruck and has published in prestigious journals such as Journal of Clinical Oncology, The EMBO Journal and Blood.

In The Last Decade

Lorenz Waldmeier

16 papers receiving 898 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sox4 Is a Master Regulator of Epithelial-Mesenchymal Transition by Controlling Ezh2 Expression and Epigenetic Reprogramming

2013 394 citations Neha Tiwari, Vijay Tiwari et al. Cancer Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lorenz Waldmeier Switzerland	10	684	330	268	150	100	17	910
Virginie Sanguin‐Gendreau Canada	17	506 0.7×	368 1.1×	148 0.6×	142 0.9×	73 0.7×	24	820
Séverine Cruet-Hennequart Ireland	14	467 0.7×	206 0.6×	158 0.6×	123 0.8×	49 0.5×	15	735
Morgane Gourlaouen United Kingdom	7	496 0.7×	175 0.5×	196 0.7×	113 0.8×	71 0.7×	9	742
Pamela Klingbeil Germany	11	680 1.0×	417 1.3×	372 1.4×	215 1.4×	36 0.4×	14	1.1k
Morihiro Higo Japan	18	584 0.9×	254 0.8×	228 0.9×	142 0.9×	35 0.3×	36	841
Agata A. Tinnirello United States	6	397 0.6×	264 0.8×	158 0.6×	91 0.6×	27 0.3×	12	592
Rajeshwari R. Valiathan United States	8	313 0.5×	250 0.8×	98 0.4×	186 1.2×	188 1.9×	10	722
Carmen Eckerich Germany	12	625 0.9×	183 0.6×	159 0.6×	97 0.6×	44 0.4×	13	890
Francesca De Bacco Italy	10	391 0.6×	359 1.1×	217 0.8×	67 0.4×	40 0.4×	13	814
Laura Gómez-Cuadrado United Kingdom	9	347 0.5×	392 1.2×	152 0.6×	100 0.7×	32 0.3×	9	745

Countries citing papers authored by Lorenz Waldmeier

Since Specialization

Citations

This map shows the geographic impact of Lorenz Waldmeier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lorenz Waldmeier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lorenz Waldmeier more than expected).

Fields of papers citing papers by Lorenz Waldmeier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lorenz Waldmeier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lorenz Waldmeier. The network helps show where Lorenz Waldmeier may publish in the future.

Co-authorship network of co-authors of Lorenz Waldmeier

This figure shows the co-authorship network connecting the top 25 collaborators of Lorenz Waldmeier. A scholar is included among the top collaborators of Lorenz Waldmeier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lorenz Waldmeier. Lorenz Waldmeier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

1.

Liu, Dongli, Cassandra J. Vandenberg, Patrizia Sini, et al.. (2025). The antibody–drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models. Therapeutic Advances in Medical Oncology. 17. 22777207–22777207. 1 indexed citations

2.

Silva, Manuel A., Sylvie Hauert, Baruch Ovadia, et al.. (2024). Tumour assessment of ROR1 levels in various adult leukaemia and lymphoma types. PLoS ONE. 19(11). e0313026–e0313026.

3.

Raso, Maria Gabriela, Kurt W. Evans, Rossana Lazcano, et al.. (2024). Heterogeneous Profile of ROR1 Protein Expression across Tumor Types. Cancers. 16(10). 1874–1874. 6 indexed citations

4.

Tolcher, Anthony W., Funda Meric‐Bernstam, Meredith McKean, et al.. (2021). NBE-002: A novel anthracycline-based antibody-drug conjugate (ADC) targeting ROR1 for the treatment of advanced solid tumors—A phase 1/2 clinical trial.. Journal of Clinical Oncology. 39(15_suppl). TPS1108–TPS1108. 18 indexed citations

5.

Beerli, Roger R., Lorenz Waldmeier, Rémy Gébleux, Francesca Pretto, & Ulf Grawunder. (2019). Abstract LB-197: NBE-002, an anthracycline-based immune-stimulatory antibody drug conjugate (iADC) targeting ROR1 for the treatment of triple-negative breast cancer. Cancer Research. 79(13_Supplement). LB–197. 8 indexed citations

6.

Hu, Eileen, Priscilla Do, Rajeswaran Mani, et al.. (2019). Abstract 1541: Evaluation of ROR1 targeted antibody drug conjugate in ROR1 positive leukemia. Cancer Research. 79(13_Supplement). 1541–1541. 1 indexed citations

7.

Beerli, Roger R., Lorenz Waldmeier, Rémy Gébleux, Francesca Pretto, & Ulf Grawunder. (2019). Abstract LB-197: NBE-002, an anthracycline-based immune-stimulatory antibody drug conjugate (iADC) targeting ROR1 for the treatment of triple-negative breast cancer. Immunology. LB–197. 1 indexed citations

8.

Waldmeier, Lorenz, et al.. (2018). Novel Antibody Drug Conjugates Targeting Tumor-Associated Receptor Tyrosine Kinase ROR2 by Functional Screening of Fully Human Antibody Libraries Using Transpo-mAb Display on Progenitor B Cells. Frontiers in Immunology. 9. 2490–2490. 18 indexed citations

9.

Gébleux, Rémy, et al.. (2017). Highly Potent, Anthracycline-based Antibody–Drug Conjugates Generated by Enzymatic, Site-specific Conjugation. Molecular Cancer Therapeutics. 16(5). 879–892. 62 indexed citations

10.

Hu, Eileen, Priscilla Do, Rajeswaran Mani, et al.. (2017). Evaluation of ROR1 Targeted Antibody Drug Conjugates in Acute and Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma. Blood. 130. 3017–3017. 1 indexed citations

11.

Waldmeier, Lorenz, et al.. (2016). Transpo-mAb display: Transposition-mediated B cell display and functional screening of full-length IgG antibody libraries. mAbs. 8(4). 726–740. 30 indexed citations

12.

Diepenbruck, Maren, Lorenz Waldmeier, Robert Ivánek, et al.. (2014). Tead2 expression levels control Yap/Taz subcellular distribution, zyxin expression, and epithelial-mesenchymal transition. Journal of Cell Science. 127(Pt 7). 1523–36. 116 indexed citations

13.

Tiwari, Neha, Vijay Tiwari, Lorenz Waldmeier, et al.. (2013). Sox4 Is a Master Regulator of Epithelial-Mesenchymal Transition by Controlling Ezh2 Expression and Epigenetic Reprogramming. Cancer Cell. 23(6). 768–783. 394 indexed citations breakdown →

14.

Waldmeier, Lorenz, et al.. (2013). The RNA-binding protein Rbfox2: an essential regulator of EMT-driven alternative splicing and a mediator of cellular invasion. Oncogene. 33(9). 1082–1092. 126 indexed citations

15.

Waldmeier, Lorenz, Nathalie Meyer‐Schaller, Maren Diepenbruck, & Gerhard Christofori. (2012). Py2T Murine Breast Cancer Cells, a Versatile Model of TGFβ-Induced EMT In Vitro and In Vivo. PLoS ONE. 7(11). e48651–e48651. 58 indexed citations

16.

Yilmaz, M. Deniz, Neha Tiwari, Lorenz Waldmeier, et al.. (2011). Transcription factor Dlx2 protects from TGFβ‐induced cell‐cycle arrest and apoptosis. The EMBO Journal. 30(21). 4489–4499. 48 indexed citations

17.

Gaiser, Carine, et al.. (2009). p28, A Novel ERGIC/cisGolgi Protein, Required for Golgi Ribbon Formation. Traffic. 11(1). 70–89. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact